PMV Pharmaceuticals To Present Updated Phase 1 Data On PC14586 At The 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Benzinga Newsdesk 3 years ago
BiotechNewsGeneral
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C
- Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutation
- Company to host KOL webinar on October 12, 2023 to review data and provide regulatory update